| Code | CSB-RA004936MB21HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Sotigalimab, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, including dendritic cells, macrophages, and B cells, where it plays a pivotal role in adaptive immunity by facilitating T cell priming and activation. Upon binding with its ligand CD40L, this interaction triggers downstream signaling cascades that enhance immune responses and promote antitumor immunity. Dysregulation of CD40 signaling has been implicated in various pathological conditions, including autoimmune disorders, inflammatory diseases, and cancer immune evasion.
Sotigalimab represents an agonistic anti-CD40 antibody originally developed for cancer immunotherapy applications. This biosimilar antibody provides researchers with a valuable tool for investigating CD40-mediated immune activation, studying dendritic cell maturation, exploring combination immunotherapy strategies, and elucidating mechanisms of antitumor immune responses. It serves as an essential reagent for immunology research, cancer biology studies, and preclinical therapeutic development.
There are currently no reviews for this product.